Skip to Content

ARCA biopharma Inc ABIO

Morningstar Rating
$3.40 +0.15 (4.62%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ABIO is trading at a 47% discount.
Price
$3.38
Fair Value
$4.24
Uncertainty
Extreme
1-Star Price
$13.31
5-Star Price
$6.77
Economic Moat
Ymtj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABIO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.25
Day Range
$3.213.42
52-Week Range
$1.563.88
Bid/Ask
$3.26 / $3.27
Market Cap
$49.30 Mil
Volume/Avg
926,192 / 1.6 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
5

Valuation

Metric
ABIO
Price/Earnings (Normalized)
Price/Book Value
1.27
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ABIO
Quick Ratio
58.76
Current Ratio
59.01
Interest Coverage
Quick Ratio
ABIO

Profitability

Metric
ABIO
Return on Assets (Normalized)
−11.45%
Return on Equity (Normalized)
−11.84%
Return on Invested Capital (Normalized)
−16.72%
Return on Assets
ABIO
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXyqldybzkfJbjn$550.4 Bil
VRTX
Vertex Pharmaceuticals IncPqwczvjXxzyxy$101.7 Bil
REGN
Regeneron Pharmaceuticals IncSdztvcklhBhbmrr$98.1 Bil
MRNA
Moderna IncJnfswtckxFzzqy$38.8 Bil
ARGX
argenx SE ADRQvlgrfvfDplgy$21.7 Bil
BNTX
BioNTech SE ADRSjckvcskLtdh$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncVhxjkwgwrSbscjgv$18.4 Bil
BMRN
Biomarin Pharmaceutical IncTxhkzqdzNhfwwvs$17.1 Bil
RPRX
Royalty Pharma PLC Class AHgwyrscbylFdhwbtn$12.5 Bil
INCY
Incyte CorpRggdqtpxyTwmznxw$11.9 Bil

Sponsor Center